Search

Terry L Burkoth

from Palo Alto, CA
Age ~84
Get Report
Also known as:
Terry I Burkoth, Terry H
Phone and address:
711 Torreya Ct, Palo Alto, CA 94303
(650) 494-2617
Related to:
Jason K Carter, 52Christopher Carter, 54Nancy Marlatt, 54John E Burdick, 73
Connected to:
Sharolyn A Burkoth, 82Maya V Burkova, 48Vladimir Burkov, 59Caryn E Burkow, 74Linda C Burkow, 67Steve C Burkow, 59Allen M Burkowsky, 60Abbie M Burks, 33Aderrica E Burks, 35Alecia Burks, 39

Terry Burkoth Phones & Addresses

  • 711 Torreya Ct, Palo Alto, CA 94303 (650) 494-2617
  • Torreya Ct, Palo Alto, CA 94303
  • 3709 Shawnee Dr, Modesto, CA 95356
  • 3465 21St St, San Francisco, CA 94110
  • Lake Bluff, IL
  • Cleveland, OH
  • 711 Torreya Ct, Palo Alto, CA 94303 (650) 224-2531

Work

Position: Retired

Education

Degree: Graduate or professional degree

Business Records

Name / Title
Company / Classification
Phones & Addresses
Terry Burkoth
Principal
Paceline Consulting
Business Consulting Services
711 Torreya Ct, Palo Alto, CA 94303

Publications

Us Patents

Non- Or Minimally Invasive Monitoring Methods

View page
US Patent:
6602678, Aug 5, 2003
Filed:
Dec 17, 2001
Appl. No.:
10/022633
Inventors:
Sung Yun Kwon - Fremont CA
Terry L. Burkoth - Palo Alto CA
Assignee:
PowderJect Research Limited - Oxford
International Classification:
C12Q 154
US Classification:
435 14, 435 4, 4352831, 435 25
Abstract:
An apparatus for sensing an analyte is described, wherein the apparatus includes an interface contact element that is used to establish an interface with a quantity of body fluid. The interface contact element is adapted to facilitate diffusion of a target analyte across the interface essentially free of net mass fluid transport. The quantity of body fluid is exposed to the interface contact element through micro-pathways. The apparatus can also include a sensing material adapted to sense the target analyte with at least one analytical method. Methods for using the apparatus in a non- or minimally invasive monitoring technique are also described.

Particle Delivery Techniques

View page
US Patent:
6893664, May 17, 2005
Filed:
Dec 17, 1998
Appl. No.:
09/216641
Inventors:
Terry Lee Burkoth - Palo Alto CA, US
David Francis Sarphie - Madison WI, US
Andrew Gordon Muddle - Cambs, GB
Linda Maree Porter - The Gap, AU
Assignee:
Powderject Research Limited
International Classification:
A61K009/14
A61K009/16
A61K047/00
A01N025/00
US Classification:
424489, 424491, 514773
Abstract:
A method is provided for in vivo or ex vivo delivery of a preparation of powdered nucleic acid molecules into vertebrate tissue for transformation of cells in the tissue using needleless injection techniques. The method can be used to deliver therapeutically relevant nucleotide sequences to cells in mammalian tissue to provide gene therapy, elicit immunity or to provide antisense or ribozyme functions. A method for providing densified processed pharmaceutical compositions is also described. The method is used to convert non-dense pharmaceutical powders or particulate formulations into densified particles optimally suited for transdermal delivery using a needleless syringe. The method is also used to optimize the density and particle size of powders and particulate formulations for subsequent transdermal delivery thereof. Densified pharmaceutical compositions formed by the present methods are also provided.

Hydrogel Particle Formulation

View page
US Patent:
7022313, Apr 4, 2006
Filed:
Aug 3, 2001
Appl. No.:
09/922218
Inventors:
Barbara Horsey O'Connor - San Carlos CA, US
Terry Lee Burkoth - Palo Alto CA, US
Steven Joseph Prestrelski - Mountain View CA, US
Yuh-Fun Maa - Millbrae CA, US
Andrew Muddle - Oxon, GB
Roderick Hafner - Basingstoke, GB
Assignee:
PowderJect Research Ltd. - Oxford
International Classification:
A61K 9/14
A61K 9/16
US Classification:
424 48, 424499, 424500, 424501
Abstract:
New compositions formed from the combination of an active substance with a hydrogel carrier moiety are provided. The compositions are suitable for use in high-velocity transdermal particle injection techniques. Methods of providing the new compositions are also provided. In addition, methods for administering pharmacologically active agent to a subject are provided. These methods are useful for delivering drugs, biopharmaceuticals, vaccines and diagnostics agents.

Spray Freeze-Dried Compositions

View page
US Patent:
7229645, Jun 12, 2007
Filed:
Jun 10, 2002
Appl. No.:
10/164594
Inventors:
Yuh-Fun Maa - Fremont CA, US
Steven J. Prestrelski - Fremont CA, US
Terry L. Burkoth - Fremont CA, US
Assignee:
Powderject Research Limited - Oxford
International Classification:
A61K 9/14
A61K 31/28
US Classification:
424489, 424499, 4241841, 4242041, 4242341, 514492
Abstract:
A process for producing a powder comprises spray freeze-drying an aqueous solution or suspension comprising a pharmaceutical agent, said solution or suspension having a solids content of 20% by weight or more. The spray freeze-dried powder may be administered to a subject via a needleless syringe.

Polymer Coated Device For Electrically Medicated Drug Delivery

View page
US Patent:
7517342, Apr 14, 2009
Filed:
Apr 29, 2003
Appl. No.:
10/425170
Inventors:
Neal Scott - Mountain View CA, US
Jerome Segal - Mountain View CA, US
Terry L. Burkoth - Palo Alto CA, US
Assignee:
Boston Scientific Scimed, Inc. - Maple Grove MN
International Classification:
A61B 17/20
US Classification:
604501, 604 20
Abstract:
The present invention relates to a catheter with an expandable distal end for delivering one or more medicaments. The catheter is manufactured with materials of construction that allow the transfer of electrical energy from the proximal end of the catheter to the distal expandable end. The catheter also has a means for controlling or manipulating the expandable distal end to expand and contract into various configurations. The distal end of the catheter is processed by a specific method of manufacturing whereby the expandable distal end is coated with one or more layers of a hydrogel copolymer wherein at least one layer of which coating encapsulates one or more medicaments and zero or more charged carriers to facilitate the electrophoretic and electro-osmostic mobilities of the medicaments.

Compositions And Kits For Treating Influenza

View page
US Patent:
7858660, Dec 28, 2010
Filed:
Jun 2, 2009
Appl. No.:
12/477105
Inventors:
Jack Nguyen - San Francisco CA, US
Gregory T. Went - Mill Valley CA, US
Paul Spence - Novato CA, US
Timothy J. Fultz - Pleasant Hill CA, US
David Chernoff - San Anselmo CA, US
Terry L. Burkoth - Palo Alto CA, US
Rowan Chapman - Burlingame CA, US
Mickey S. Urdea - Alamo CA, US
Assignee:
Adamas Pharmaceuticals, Inc. - Emeryville CA
International Classification:
C07H 19/056
A61K 31/215
A61K 31/166
A61K 31/16
A61K 31/7056
A61K 31/13
C07D 315/00
C07D 307/12
C07C 69/75
C07C 61/08
C07C 217/52
US Classification:
514529, 514629, 514 43, 514659, 514661, 514662, 514563, 514459, 536 287, 549424, 560128, 562507, 564456, 564458, 564459
Abstract:
Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.

Compositions And Kits For Treating Influenza

View page
US Patent:
7981930, Jul 19, 2011
Filed:
Feb 29, 2008
Appl. No.:
12/040856
Inventors:
Jack Nguyen - San Francisco CA, US
Gregory T. Went - Mill Valley CA, US
Paul Spence - Mill CA, US
Timothy J. Fultz - Pleasant Hill CA, US
David Chernoff - San Rafael CA, US
Terry L. Burkoth - Palo Alto CA, US
Rowan Chapman - Burlingame CA, US
Mickey S. Urdea - Alamo CA, US
Assignee:
Adamas Pharmaceuticals, Inc. - Emeryville CA
International Classification:
A61K 31/7056
A61K 31/351
A61K 31/215
A61K 31/196
A61K 31/195
A61K 31/131
C07H 19/056
C07D 309/28
C07C 69/75
C07C 61/22
C07C 229/48
C07C 211/38
US Classification:
514529, 514629, 514 43, 514659, 514661, 514662, 514459, 514563, 536 287, 549424, 560128, 562507, 564456, 564458, 564459
Abstract:
Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.

Production Of Hard, Dense Particles

View page
US Patent:
20030026842, Feb 6, 2003
Filed:
Jun 10, 2002
Appl. No.:
10/164413
Inventors:
Steven Prestrelski - Fremont CA, US
Terry Burkoth - Fremont CA, US
Yuh-Fun Maa - Fremont CA, US
International Classification:
A61K009/14
B02C019/00
US Classification:
424/489000, 241/001000
Abstract:
Hard, dense particles of a pharmaceutical agent, suitable for administration to a subject via a needleless syringe are described. The particles are prepared by a multi step process that entails forming particles of a first size where the particles are an admixture of a pharmaceutical agent and a macromolecular carrier and the admixture has a first glass transition temperature; admixing a plasticizer that lowers the first glass transition temperature of the admixture to a second glass transition temperature which is below the first glass transition temperature; maintaining the articles at a temperature above the second glass transition temperature for a time period adequate to cause the particles to shrink and/or collapse; removing the plasticizer from the particles to yield modified particles having an increased glass transition temperature; recovering the modified particles; and then storing the recovered particles.
Control profile
Terry L Burkoth from Palo Alto, CA, age ~84 Get Report